Study Cerecetam on Aphasia in Patients with CVA

Abstract

Cerebrovascular Attack is caused by decreased or no supply of blood to parts of brain due to clot formation in blood vessels (Ischemic stroke) or due to rupture of blood vessels (Hemorrhagic stroke) or due to Transient ischemic stroke which is the warning sign of stroke which leads to chief complaints of head ache, slurred speech/aphasia, weakness of limbs etc. Aphasia is an acquired neurogenic disorder caused by damage to cerebral cortex, bacterial infections or rarely due to neurogenerative disorder. There are 5 types of aphasia which is classified based on formation of infracts in regions of brain. Cerecetam is a neutrophil agent that show effect on speech improvement which is available in tablets(800mg), Ampoule(15ml), vial(60ml) each ml containing 200mg are available. The specific method followed was observational prospective study with time horizon of longitudinal study was conducted on 150 patients who are suffering with CVA and having c/o of Aphasia and slurred speech in Lalitha super specialty hospital with study period of 6 months and the data was analyzed quantitative and qualitative method. As for the method better results found by using assessment scale patients were assessed and a final report was prepared whether there is improvement in speech or no improvement of speech after administration of cerecetam with frequency of BD/TID for 2 weeks. The result x2 is 39.78 at Df 4 with significance level of 0.05, P value <0.05. The observed conclusion was Cerecetam plays a significant role in speech improvement in patients diagnosed with CVA and having c/o of slurred speech/aphasia. In Subcortical aphasia (66.6% cases), Broca’s aphasia (24% cases), Global aphasia (4.1% cases), Cortical Aphasia (3.3% cases) there is speech improvement. Where as in Wernicke’s Aphasia (1.6% cases) the drug cerecetam has less effect.